Discover our certified test execution matrix, analytical method development platforms, and end-to-end biological characterization frameworks engineered to meet FDA, EMA, and NMPA filing standards.
The intersection of international harmonization, digital analytics, and stringent safety criteria is transforming quality assessment from retrospective batch testing to continuous analytical verification.
Analytical method development has shifted toward AQbD principles, requiring systemic risk evaluation, Method Operable Design Regions (MODR), and quantitative robustness testing. Modern bio-manufacturers require analytical protocols validated for precision, linearity, limit of detection (LOD), and cross-laboratory reproducibility before filing IND/NDA submissions.
Unlike single-molecule synthetics, complex botanical therapeutics and dietary supplements demand multi-component characterization. High-Performance Thin-Layer Chromatography (HPTLC), UPLC-Q-TOF-MS/MS, and 2D-NMR fingerprinting have emerged as imperative standards to identify chemical batch variation, harvest inconsistencies, and adulteration.
Global regulators (US FDA, EMA, Health Canada) enforce stringent thresholds on elemental impurities (ICH Q3D), residual solvents (ICH Q3C), mutagenic nitrosamines (ICH M7), and pesticide multi-residues. Validated testing protocols guarantee compliance across global borders, preventing catastrophic product recalls.
Multinational pharma leaders, nutraceutical conglomerates, and cosmetic innovators demand turnkey contract manufacturing and testing partners who reduce technical translation friction.
Global buyers prioritize CROs that track samples from wild botanical geo-origin authentication to chromatographic release assays, providing immutable audit trails.
Procurement teams require validation dossiers that include specificity, recovery, intermediate precision, and forced degradation data for instantaneous regulatory filing.
By coupling testing development with pilot extraction, clients compress lead times from chemical assay prototyping to commercial production by up to 45%.
Confidential contract research and strictly managed proprietary parameters protect molecular targets, extraction formulations, and chemical fingerprints globally.
How MedGence leverages integrated pilot plants, automated chromatography, and continuous data capture to deliver unmatched efficiency and supply chain resilience.
Our Changsha testing facilities integrate modern Laboratory Information Management Systems (LIMS) with high-throughput HPLC/GC/LC-MS platforms. This eliminates human transcription errors, provides automated baseline corrections, and generates tamper-proof 21 CFR Part 11 compliant digital documentation.
Transition seamlessly from micro-scale bench chromatography to multi-ton industrial extractors. Our in-house pilot plants and co-managed manufacturing centers apply the exact critical process parameters (CPPs) validated in discovery, preventing batch losses during scale-up.
With over 400 single-herb pharmacopeial standards optimized and raw material supply networks covering authentic Chinese medicinal origins (Geo-authentic Daodi herbs), our supply chain insulates global clients against seasonal supply shortages and pricing volatility.
Customized analytical suites aligned with specific target endpoints, dosage dynamics, and legal documentation requirements.
Quantification of bioactive markers (polysaccharides, total ginsenosides, flavonoids) using HPLC-DAD and spectrophotometric assays. Complete stability testing under ICH conditions (accelerated and long-term storage) to support shelf-life substantiation on finished dosage units including powders, capsules, and liquids.
Rigorous analytical packages required for Botanical Drug Development Guidance. We perform multi-laboratory method validation, characterization of active fraction mechanisms, in vitro target affinity assays, and GLP-compliant animal toxicology (acute LD50, sub-chronic toxicity, Ames genotoxicity) to build full regulatory portfolios.
Validation of active transdermal delivery constituents, anti-inflammatory and tyrosinase inhibition bioassays in cell culture, skin irritation (OECD 439), and phototoxicity testing. Verifiable claims substantiation for natural cosmetics seeking clean-label certification in European and North American markets.
A systematic, phase-gated execution plan engineered to eliminate regulatory bottlenecks and ensure analytical precision at every stage.
Phytochemical extraction profiling, identification of marker compounds, screening by harvest origin and phenological seasonality.
Protocol establishment under ICH Q2(R2): specificity against matrix, accuracy, repeatability, ruggedness, and limit determinations.
Execution of in vitro cell panels, GLP animal toxicity profiles, pharmacokinetic evaluation, and Phase I–IV clinical proof-of-concept.
Transfer of validated parameters to GMP pilot reactors and commercial batching in oral solutions, tablets, capsules, and distillates.
Authoritative insights into analytical protocols, international compliance dossiers, intellectual property, and supply chain timelines.
Select from our validated research packages and CDMO services below to accelerate your development schedule.
Partner with MedGence (Yineng Pharma) for ICH-standard test validation, phytochemical assay development, and reliable contract bio-manufacturing. Connect directly with our scientific team.
